carcinoembryonic antigen

(redirected from Cancer Antigens)
Also found in: Dictionary, Medical.
Related to Cancer Antigens: CA125 ovarian cancer antigen

carcinoembryonic antigen

[¦kärs·ən·ō‚em·brē¦än·ik ′ant·i·jən]
(immunology)
A glycoprotein found in tissues of the fetal gut during the first two trimesters of pregnancy and in the peripheral blood of individuals with some forms of cancer, such as digestive-system or breast cancer.
References in periodicals archive ?
This meant that the immune system 'self-selected' the cancer antigens to respond to and did not react against other healthy parts of the body.
Some important cancer antigens that serve as diagnostic and prognostic biomarkers of cancer are summarized in the Table.
We fight cancer with immunotherapy by creating antibodies against cancer antigens.
The GM-CSF molecule attracts immune cells to the vaccine site, where the immune cells encounter pancreas cancer antigens.
With the licensing of this important portfolio of clinically-validated cancer antigens, we strengthen our commitment to developing innovative immunotherapies against a wide variety of oncology targets, employing our unique APC targeted delivery methodology.
In addition, genes involved in coding cancer antigens have been identified, along with the immunogenic peptides associated with these antigens.
For those who order the blood-panel tests, there also will be an optional thyroid test for $15 and a test for prostatic cancer antigens for $25.
The presentation examines the frequency and functionality of the T cell response not only specific to its target antigen, but to other prostate cancer antigens.
Adaptimmune`s proprietary T-cell receptor (TCR) technology enables to genetically optimize TCRs in an effort to equip them to recognize and bind cancer antigens that are presented in small quantities on the surface of a cancer cell, whether of intracellular or extracellular origin, thus initiating cell death.
More specifically, Oncimmune specializes in detection of autoantibodies against cancer antigens in order to build a panel of autoantibodies that serve as a blood biomarker test for early detection of specific cancers.
These relevant peptide cancer antigens constitute the basis for developing a range of rationally designed cancer immunotherapies including cancer vaccines, peptide-targeting compounds such as antibodies, soluble T-cell receptors and adoptive cellular therapies.
The granted United States Patent protects additional cancer antigens which Cancer Vac can use in the commercialization of its immunotherapy program.

Full browser ?